2. Academic Validation
  3. Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma

Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma

  • NPJ Precis Oncol. 2025 Aug 16;9(1):289. doi: 10.1038/s41698-025-01076-4.
Catherine Z Beach # 1,  Christopher A Febres-Aldana # 2,  Juan Luis Gomez Marti 3,  Saeed Asiry 3,  Tamika Wong 4,  John A Boockvar 4,  Randy S D'Amico 4,  Romel Somwar 5 6,  Monika A Davare 7,  Morana Vojnic 8
Affiliations

Affiliations

  • 1 Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA.
  • 2 Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
  • 3 Department of Pathology, Lenox Hill Hospital, New York, NY, USA.
  • 4 Department of Neurological Surgery, Lenox Hill Hospital, Northwell, New York, NY, USA.
  • 5 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 6 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 7 Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA. davarem@ohsu.edu.
  • 8 Rutgers Cancer Institute, New Brunswick, NJ, USA. mv858@cinj.rutgers.edu.
  • # Contributed equally.
PMID: 40819143 DOI: 10.1038/s41698-025-01076-4
Abstract

Glioblastoma is an aggressive and treatment-refractory primary brain tumor with limited therapeutic options and high recurrence. The molecular heterogeneity of glioblastoma poses a significant challenge to therapeutic development, as targeted therapies have mostly failed in small-scale clinical trials, underscoring the need for comprehensive next-generation Sequencing (NGS) characterization to identify mechanisms of resistance. In this study, we identify and functionally characterize a novel amplified fusion, MDM2 (exon 1)::PDGFRA (exon 8), mediating resistance to cetuximab in an EGFR-amplified glioblastoma. The fusion results in a truncated PDGFRA isoform, in vitro assays demonstrate that MDM2::PDGFRA acts as a constitutively active oncogenic driver with a distinct sensitivity profile to tyrosine kinase inhibitors. Analysis of a glioblastoma cohort indicates PDGFRA structural variants often co-occur with amplification and may serve as biomarkers. These findings highlight the importance of repeat NGS profiling in clinical management and provide a translational framework for identifying and targeting emergent fusion-driven alterations.

Figures
Products